April 12, 2023JAMA Cardiology59 citationsOpen Access
View Full PaperComprehensive Cardiovascular Magnetic Resonance Tissue Characterization and Cardiotoxicity in Women With Breast Cancer
Structured PICO
Are CMR tissue biomarkers useful in identifying traditional cancer therapy-related cardiac dysfunction (CTRCD) risk in women with ERBB2-positive breast cancer receiving anthracycline and trastuzumab?
P
Population
Women with ERBB2-positive breast cancer receiving sequential anthracycline and trastuzumab therapy
I
Intervention
Cardiovascular Magnetic Resonance (CMR) tissue characterization (biomarkers for inflammation and edema)
O
Outcome
Cancer therapy-related cardiac dysfunction (CTRCD) risk, ventricular remodeling, BNP elevation, LVEF, and myocardial strainsurrogate
Transient increases in CMR tissue biomarkers of inflammation and edema during anthracycline and trastuzumab therapy do not predict traditional cancer therapy-related cardiac dysfunction.
Abstract
In women with ERBB2-positive breast cancer receiving sequential anthracycline and trastuzumab therapy, CMR tissue biomarkers suggest inflammation and edema peaking early during therapy and were associated with ventricular remodeling and BNP elevation. However, the increases in CMR biomarkers were transient, were not associated with LVEF or myocardial strain, and were not useful in identifying traditional CTRCD risk.